Literature DB >> 28115013

Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

Jérémie Sellam1,2, Elodie Rivière3, Alice Courties4, Paul-Olivier Rouzaire5, Barbara Tolusso6, Edward M Vital7, Paul Emery7, Gianfranco Ferracioli6, Martin Soubrier8, Bineta Ly3, Houria Hendel Chavez9, Yassine Taoufik9, Maxime Dougados10, Xavier Mariette11,12.   

Abstract

Entities:  

Year:  2017        PMID: 28115013      PMCID: PMC5256546          DOI: 10.1186/s13075-017-1221-4

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


× No keyword cloud information.

Erratum

Unfortunately, after publication of this article [1], it was noticed that the name of Gianfranco Ferracioli was incorrectly spelled as Gianfranco Ferraciolli. The corrected author list can be seen above and the original article has been updated to correct this error.
  1 in total

1.  Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

Authors:  Jérémie Sellam; Elodie Rivière; Alice Courties; Paul-Olivier Rouzaire; Barbara Tolusso; Edward M Vital; Paul Emery; Gianfranco Ferraccioli; Martin Soubrier; Bineta Ly; Houria Hendel Chavez; Yassine Taoufik; Maxime Dougados; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2016-12-13       Impact factor: 5.156

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.